MRPL13 is a metastatic and prognostic marker of breast cancer: A silico analysis accompanied with experimental validation

Abstract Background: Although progress has been made in accurate diagnosis and targeted treatments, breast cancer (BC) patients with metastasis still present a grim prognosis. With the continuous emergence and development of new personalized and precision medicine targeting specific tumor biomarkers, there is an urgent need to find new metastatic and prognostic biomarkers for BC patients. Methods: We commit to identify genes that associate with metastasis and prognosis in BC by a silico analysis accompanied with experimental validation. Results: A total of 25 overlap differentially expressed genes were identified. Ten hub genes (namely MRPL13, CTR9, TCEB1, RPLP0, TIMM8B, METTL1, GOLT1B, PLK2, PARL and MANBA) were identified and confirmed. MRPL13, TCEB1, GOLT1Bwere shown be associated with the worse over survival (OS) and were optionally chosen for further verification by western blot. Only MRPL13 was found associated with cells invasion, and the expression ofMRPL13 in metastatic BC was significant higher than in primary BC. Conclusion: We proposed MRPL13 could be a potential novel biomarkerfor the metastasis and prognosis of breast cancer.